Q3 Revenue Jumps 49% but Gross Margin Collapses to 57%, Net Loss Swings to $33M
HIMS sits 67% above its 52-week low of $13.74 on elevated volume (3.7× avg).
Summary
Revenue came in at $890.4 million, up 49% year-over-year, with international revenue up more than 300% and subscribers up 13% to 2.788 million. The problem is profitability: gross margin fell to 57% from 74% a year ago, and the company swung to a $33.0 million net loss, or a loss of 14 cents per share, from $15.8 million of net income in Q3 2025. Adjusted EBITDA of $82.4 million was roughly flat versus $78.4 million, and free cash flow dropped to $26.0 million from $79.4 million. Guidance is the bigger issue — Q4 revenue of $875 million to $895 million implies essentially no sequential growth off Q3, and Q4 Adjusted EBITDA of $70 million to $90 million is an 8% to 10% margin, down from 9% this quarter. Full-year 2026 Adjusted EBITDA guidance was cut to $257 million to $277 million, an 8% to 9% margin, while revenue guidance was tightened to $3.13 billion to $3.15 billion. The stock was already down 10.31% at $23.32 ahead of the print, so the margin compression and flat Q4 top line land on an already nervous tape. The 5:00 p.m. ET call will be where management defends the marketing spend pacing and the weight-loss pivot.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Hims & Hers cut full-year 2026 Adjusted EBITDA guidance to $257 million to $277 million, an 8% to 9% margin, while tightening revenue guidance to $3.13 billion to $3.15 billion.
At the time of this announcement, HIMS was trading at $22.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $13.74 to $42.70. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: BusinessWire.